Evidence map›Paper›PMID 31245299›Full record

ReviewFrontiers in cellular and infection microbiology2019

Disease Tolerance in

Stephanie J Melchor, Sarah E Ewald

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 44 citations in OpenAlex.

  1. Quercetin ReducesInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Therapeutic effect of baicalein as an antiparasitic agent againstJournal of Zhejiang University. Science. B · 2025
    Article
  4. Parasitology · 2025
    Article
  5. Article
  6. Article
  7. Diseases Caused by and Behaviors Associated withPathogens (Basel, Switzerland) · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Amphibian infection tolerance to chytridiomycosis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. RecombinantVaccines · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Stephanie J MelchorDepartment of Microbiology, Immunology and Cancer Biology and the Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
Sarah E EwaldDepartment of Microbiology, Immunology and Cancer Biology and the Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
University of Virginia · US

Funding

Identification of the non-proteolytic mechanism of NLRP1 activationK22AI116727 · NIAID · UNIVERSITY OF VIRGINIA · PI EWALD, SARAH E. · 2016 to 2017
$269k
NIAID NIH HHS K22 AI116727
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsDisease ResistanceHost-Parasite InteractionsHumansImmune ToleranceImmunity, InnateInflammationToxoplasmaToxoplasmosiscachexiachronic infectioninnate immunityparasiteresistancetoleranceToxoplasma gondii

Identifiers

PMID31245299
PMCPMC6563770
OpenAlexW2968919017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.